Respiratory Syncytial Virus

File Description SizeFormat 
Jha Openshaw Review RSV ERS monograph souvenir version 2016.pdfAccepted version1.04 MBAdobe PDFView/Open
Title: Respiratory Syncytial Virus
Authors: Jha, A
Jarvis, H
Fraser, C
Openshaw, PJ
Item Type: Chapter
Publication Date: 2016-12-01T07:00:32Z
Abstract: RSV infection has an estimated global incidence of 33 million cases in children <5 years of age, with 10% requiring hospital admission and up to 199 000 dying of the disease. There is growing evidence that severe infantile RSV bronchiolitis, a condition characterised by an inflammatory reaction to the virus, is associated with later childhood wheeze in some vulnerable children; however, a direct causal relationship with asthma has not yet been established. RSV infection is also increasingly recognised as a cause of morbidity and mortality in those with underlying airway disease, the immunocompromised and frail elderly persons. Novel molecular-based diagnostic tools are becoming established, but treatment remains largely supportive, with palivizumab the only licensed agent currently available for passive prophylaxis of selected pre-term infants. While effective treatments remain elusive, there is optimism about the testing of novel antiviral drugs and the development of vaccines that may induce long-lasting immunity without the risk of disease augmentation.
Editors: Hui, DS
Rossi, GA
Johnston, S
Issue Date: 1-Jun-2016
URI: http://hdl.handle.net/10044/1/33690
DOI: https://dx.doi.org/10.1183/2312508X.10010315
ISBN: 978-1-84984-069-9
Publisher: European Respiratory Society
Start Page: 84
End Page: 109
Journal / Book Title: SARS, MERS and other Viral Lung Infections
ERS Monograph
Copyright Statement: This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in SARS, MERS and other Viral Lung Infections, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the copyright owner, the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties.
Sponsor/Funder: Wellcome Trust
Funder's Grant Number: 087805/Z/08/Z
Keywords: Respiratory Syncytial Virus, Human
Bronchiolitis, Viral
Respiratory Syncytial Virus Vaccines
Publication Status: Published
Article Number: 5
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx